Effects of an extended MRI approval of an implantable spinal cord stimulation device on compliance with manufacturer's recommendations
Pain Practice · 2025
DOI: 10.1111/papr.70022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pain Practice, 2025. Verfasst von Marco Reining und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pain Medicine and Palliative Care, SRH Wald-Klinikum Gera GmbH, Gera, Germany. Hauptthemen laut MEDLINE: Spinal Cord Stimulation, Magnetic Resonance Imaging, Device Approval, Implantable Neurostimulators. Die Arbeit nennt 29 Literaturangaben. Gefördert von: SRH Wald-Klinikum Gera GmbH.
Abstract (Originalsprache)
Objective
The current approval for all available spinal cord stimulation (SCS) devices set several limitations for magnetic resonance imaging (MRI). As a result, most of the necessary examinations are not possible within the scope of the restrictive approvals and, if legally permitted, must be carried out off‐label. This retrospective subgroup analysis investigates if the currently extended MRI approval of one specific device allows more MRI scans to be conducted within the manufacturer's recommendations. Materials and Methods Technical MRI data (saved in the DICOM headers) and medical treatment data for all MRI examinations on patients with Proclaim® implantable pulse generators (IPG; Proclaim® spinal cord stimulation systems, Abbott Laboratories, Plano, TX, USA) were examined. Due to a major change in our standard operating procedures for MRI scans in 2019, the two time periods (before and after 2019) were separately analyzed.
Results
We identified 62 MRI scans with the IPG. The entire implanted system was approved for MRI examinations in just over 50% of the cases, regardless of old and new approval. Options for lead placement were expanded in the new approval; however, this did not significantly improve the number of MR conditional devices. By contrast, for a higher specific absorption rate, significantly more scans within the recommendations are possible in Period 2 ( p = 0.011). However, the number of possible scans did not reach statistical significance in Period 1 ( p = 0.078). No device‐related adverse events were noted.
Conclusion
The new MRI approval is suitable for performing more scans within the manufacturer's specifications. Cervical leads remain problematic because longer leads are required, and the lower impedances inhibit the MRI mode.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pain Medicine and Palliative Care, SRH Wald-Klinikum Gera GmbH, Gera, Germany.
- SRH Mobile University, Riedlingen, Germany.
- Department of Neurosurgery, University Hospital Leipzig, Leipzig, Germany.
- Department of Diagnostic and Interventional Radiology, SRH Wald-Klinikum Gera GmbH, Gera, Germany.
- Friedrich-Schiller-University of Jena, Jena, Germany.
- SRH University of Applied Sciences Heidelberg, Heidelberg, Germany.
ORCID-Profile: Marco Reining
Förderung
- SRH Wald-Klinikum Gera GmbH
Zitieren
APA
Reining, M., Winkler, D., Kirchhof, K., Boettcher, J., & Kretzschmar, M. (2025). Effects of an extended MRI approval of an implantable spinal cord stimulation device on compliance with manufacturer's recommendations. Pain Practice. https://doi.org/10.1111/papr.70022
Vancouver
Reining M, Winkler D, Kirchhof K, Boettcher J, Kretzschmar M. Effects of an extended MRI approval of an implantable spinal cord stimulation device on compliance with manufacturer's recommendations. Pain Practice. 2025. doi:10.1111/papr.70022
BibTeX
@article{Reining2025,
author = {Reining, Marco and Winkler, Dirk and Kirchhof, Klaus and Boettcher, Joachim and Kretzschmar, Michael},
title = {Effects of an extended MRI approval of an implantable spinal cord stimulation device on compliance with manufacturer's recommendations},
journal = {Pain Practice},
year = {2025},
doi = {10.1111/papr.70022}
}
EUVIMED